Showing 3861-3870 of 6035 results for "".
- A Daily Orange May Reduce AMD Risk, Study Findshttps://modernod.com/news/a-daily-orange-may-reduce-amd-risk-study-finds/2479986/People who consume at least one orange per day have a 60% lower risk of developing age-related macular degeneration (AMD) 15 years later compared with those who do not eat oranges, a study has found, according to a report in Medscape.
- Q Biomed Extends its Exclusive Option Agreement With Washington University for Glaucoma Detection Biomarkerhttps://modernod.com/news/q-biomed-extends-its-exclusive-option-agreement-with-washington-university-for-glaucoma-detection-biomarker/2479989/Q BioMed has announced that it is extending its option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will continue to evaluate the feasibility and
- U.S. Court Rejects Allergan Bid to Shield Patents Through Tribe Dealhttps://modernod.com/news/u-s-court-rejects-allergan-bid-to-shield-patents-through-tribe-deal/2480000/A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan to shield patents from review by an administrative court by transferring them to a Native American tribe, according to a
- Alcon Introduces Ngenuity 3D Visualization System with Datafusion Vitreoretinal Surgery Devicehttps://modernod.com/news/alcon-introduces-ngenuity-3d-visualization-system-with-datafusion-vitreoretinal-surgery-device/2480001/Alcon launched the new Ngenuity 3D Visualization System with Datafusion at the 2018 American Society of Retina Specialists (ASRS) annual meeting. With the addition of the Datafusion software, Ngenuity now also offers integration with the Constellation Vision System for vitreoretinal surgery. The
- Bausch + Lomb Retina News, Eventshttps://modernod.com/news/bausch-lomb-retina-news-events/2480011/In advance of this week’s ASRS meeting, Bausch + Lomb Vice President and general manager of Surgical, Chuck Hess, distributed a customer letter to surgeons providing them an update on our progress in retina. The letter is below: Dear Eye Care Professional: At this time last y
- EyeSouth Partners Develops of Physician Advisory Boardhttps://modernod.com/news/eyesouth-partners-develops-of-physician-advisory-board/2480041/As part of its continuing focus on the highest quality patient outcomes, EyeSouth Partners, a network of integrated eye care practices located throughout the Southeast, announced the formation of its physician advisory board. Its responsibilities will include overseeing clinical policies and proc
- Alcon to Showcase New Products, Commitment to ECP Education at 2018 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-new-products-commitment-to-ecp-education-at-2018-optometrys-meeting/2480083/Alcon will introduce new products and educational resources to eye care professional (ECP) and paraoptometric audiences at this year’s American Optometric Association (AOA) Optometry’s Meeting taking place June 20-24 in Denver. Notably, Leatrice Eiseman, executive director at the Pantone C
- Allergan Announces Former Abbott Executive to Join Board of Directors as Part of “Refreshment Process”https://modernod.com/news/allergan-announces-former-abbott-executive-to-join-board-of-directors-as-part-of-refreshment-process/2480087/Allergan on Thursday said that former Abbott Laboratories executive Thomas Freyman will be joining its board with immediate effect. CEO Brent Saunders remarked “[Freyman] has nearly four decades of industry experience including finance leadership and serving on multiple public boards, makin
- Group of Takeda Shareholders Call Proposed Shire Purchase “Height of Madness”https://modernod.com/news/group-of-takeda-shareholders-call-proposed-shire-purchase-height-of-madness/2480115/A group of Takeda shareholders have criticized the company’s deal to buy Shire as “the height of madness,” raising concerns over the level of debt that will need to be taken on to fund the purchase, the Financial Times reported. The group hold just over 1 percent of Takeda’
- Orasis Pharmaceuticals Closes $13 Million Series B Financinghttps://modernod.com/news/orasis-pharmaceuticals-closes-13-million-series-b-financing/2480119/Privately-held Orasis Pharmaceuticals announced the closing of a $13 million Series B financing to be used to advance Orasis’s lead product candidate, CSF-1, an eye drop being developed for the treatment of presbyopia symptoms, through completion of its phase 2b clinical trial. The proceeds will